Patents by Inventor Sabine Zitzmann

Sabine Zitzmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230072421
    Abstract: A compound of general formula (I): wherein: n is 1, 2 or 3; R1, R2, R3 and R4, independently represent OH or Q; and 20 Q represents a tissue-targeting moeity selected from the group consisting of or a stereoisomer, a hydrate, a solvate, or a salt thereof, or a mixture of same, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said 25 compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of soft tissue diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 24, 2020
    Publication date: March 9, 2023
    Applicants: Bayer AS, Bayer Aktiengesellschaft
    Inventors: Niels BÖHNKE, Sabine ZITZMANN-KOLBE, Stefanie HAMMER, Sven WITTROCK, Donald BIERER, Thorsten POETHKO, Hans BRIEM, Holger Magnus STEUBER, Martina SCHÄFER, Robin Michael MEIER, Arif CELIK, Cornelia PREUSSE, Antje ROTTMANN, Nicolas WERBECK, Alexander KRISTIAN, Bård INDREVOLL, Alan CUTHBERTSON, Alex PAPPLE
  • Publication number: 20220118123
    Abstract: The present invention covers combinations of at least two components, component A and component B, comprising component A being PSMA-TTC, and component B being an antiandrogen selected form AR antagonists such as from cyproterone acetate, bicalutamide, flutamide, nilutamide, enzalutamide, apalutamide, darolutamide or keto-darolutamide, or an AR degrader such as ARV-110, or an ARN-terminal domain binder such as EPI-506, or an antisense oligonucleotide that reduces AR expression such as EZN-4176 or AZD-5312, or an androgen synthesis inhibitor such as abiraterone, particularly abiraterone acetate, seviteronel, galeterone, orteronel or ketoconazole, or a dual AR antagonist and androgen synthesis inhibitor such as ODM-204. Another aspect of the present invention covers the use of such combinations as described herein for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of a hyper-proliferative disease.
    Type: Application
    Filed: February 17, 2020
    Publication date: April 21, 2022
    Applicants: Bayer Aktiengesellschaft, BAYER AS
    Inventors: Stefanie HAMMER, Urs Beat HAGEMANN, Bernard HAENDLER, Pascale LEJEUNE, Sabine ZITZMANN-KOLBE, Christoph SCHATZ, Jenny KARLSSON
  • Publication number: 20130028838
    Abstract: This invention relates to radioactive tyrosine derivatives for imaging bone metastases, a method for imaging or diagnosing bone metastases, compositions and kits for imaging bone metastases.
    Type: Application
    Filed: February 4, 2011
    Publication date: January 31, 2013
    Applicant: PIRAMAL IMAGING SA
    Inventors: Sabine Zitzmann-Kolbe, Keith Graham
  • Publication number: 20110177002
    Abstract: The invention pertains to a compound for detecting cell death. According to the invention, the compound comprises a cyclic polyamine unit for the complexation of a bi- or trivalent metal ion. The compound of the invention may contain a reporting tag like fluorescein or a radioisotope including substituent.
    Type: Application
    Filed: July 14, 2009
    Publication date: July 21, 2011
    Applicant: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
    Inventors: Sabine Zitzmann-Kolbe, Ulrike Bauder-Wuest, Michael Eisenhut, Doerte Oltmanns
  • Publication number: 20090130020
    Abstract: This invention relates to novel compounds F-18 radio-labeled amino-alcohols suitable for labeling or already labeled by 18F methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).
    Type: Application
    Filed: September 11, 2008
    Publication date: May 21, 2009
    Inventors: Lutz Lehmann, Mathias Berndt, Dietmar Berndorff, Sabine Zitzmann-Kolbe, Ulrike Bauder-Wust, Martin Schafer, Uwe Haberkorn, Michael Eisenhut, Armin Runz
  • Publication number: 20080170993
    Abstract: The present invention relates to nucleoside analogues and more particularly to labeled nucleoside analogues. It has been found new thymidine analogues can be stably labeled with a detectable label moiety. Further the present invention relates to methods of making above compounds and use of such compounds for diagnostic imaging of tumor cells and/or treatment of proliferative diseases. In addition, the present invention relates to the preparation and use of positron emitting compounds for positron emission tomography (PET). A kit is also disclosed.
    Type: Application
    Filed: October 24, 2007
    Publication date: July 17, 2008
    Inventors: Ananth SRINIVASAN, Ulrike Voigtmann, Mathias Berndt, Keith Grahan, Sabine Zitzmann, Lutz Lehmann, Ansgar Fitzner